The legal advice provided by Wolf Theiss concentrated on drafting and revising the contracts for the planning and construction of the technologically complex production facility.
€700m (including infrastructural measures) have been budgeted for the project, which will also generate 500 new jobs. The new facility, scheduled to go into operation in 2021, will produce biopharmaceutical products by means of cell cultures.
Wolf Theiss Partner Karl Koller (Practice Group Real Estate), with his considerable experience in real estate developments and transactions, led the project. Partner Thomas Anderl (Practice Group Construction), a registered master builder and lawyer specialised in construction law, also contributed to its successful conclusion.